CARsgen Therapeutics Holdings Limited (HKG: 2171) announced, in a voluntary business update, that CT0596, an allogeneic CAR T‑cell product targeting BCMA, has completed first patient dosing in its registrational Phase I clinical trial in China for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM). Investigator‑initiated trial (IIT) results for CT0596 were previously presented as a poster at the 2026 Annual Congress of the European Hematology Association (EHA).
Development Milestone
| Item | Detail |
|---|---|
| Company | CARsgen Therapeutics Holdings Limited (HKG: 2171) |
| Milestone | First patient dosed – registrational Phase I clinical trial |
| Product | CT0596 – allogeneic BCMA‑targeted CAR T‑cell therapy |
| Platform | CARsgen’s proprietary THANK‑u Plus® |
| Indication | Relapsed/refractory multiple myeloma (R/R MM) |
| Region | China (registrational trial) |
| Prior Data Disclosure | IIT results presented as poster at EHA 2026 Annual Congress |
| Next Steps | Continued enrollment and evaluation in registrational Phase I; timelines Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: CT0596, an allogeneic (off‑the‑shelf) BCMA‑targeted CAR T‑cell therapy – targeting B‑cell maturation antigen, the validated antigen of choice in multiple myeloma cell therapy.
- Platform: Developed using CARsgen’s proprietary THANK‑u Plus® platform, the company’s in‑house allogeneic CAR‑T engineering technology.
- Off‑the‑Shelf Advantage: As an allogeneic product, CT0596 can be manufactured in advance from donor cells, eliminating the vein‑to‑vein waiting time of autologous CAR‑T – a critical benefit for rapidly progressing R/R MM patients.
- Early Clinical Signals: Previous IITs demonstrated preliminary favorable tolerability and encouraging efficacy signals in both R/R MM and primary plasma cell leukemia.
- Label Expansion Plans: Further investigation is planned in additional plasma cell malignancies and in autoimmune diseases mediated by autoreactive plasma cells – extending the BCMA‑directed allogeneic approach beyond oncology.
Trial & Evidence Snapshot
| Attribute | Detail |
|---|---|
| Current Trial | Registrational Phase I, China – first patient dosed |
| Prior Studies | Investigator‑initiated trials (IITs) in R/R MM and primary plasma cell leukemia |
| Tolerability | Preliminary favorable tolerability (IIT) |
| Efficacy | Encouraging efficacy signals (IIT) |
| Congress Disclosure | EHA 2026 poster presentation |
| Detailed Data | Available via corporate website www.carsgen.com |
Company Profile & Pipeline Strategy
- Focus: CARsgen is a biopharmaceutical company developing innovative CAR T‑cell therapies for unmet clinical needs including hematologic malignancies, solid tumors and autoimmune diseases.
- End‑to‑End Capability: Established capabilities spanning target discovery, preclinical research, clinical development and commercial‑scale production of CAR T‑cell therapies.
- In‑House Technology & Global Rights: Novel proprietary technologies and a pipeline with global rights, addressing existing CAR‑T challenges – improving safety, enhancing solid tumor efficacy and reducing treatment costs.
- Mission: To become a global biopharmaceutical leader delivering innovative, differentiated cell therapies that make cancer and other diseases curable.
Market Impact & Outlook
- Registrational Pathway Signal: First‑patient‑dosed status in a registrational Phase I trial marks CT0596’s formal entry onto the approval‑oriented track in China – a step ahead of typical exploratory‑phase allogeneic CAR‑T programs.
- Allogeneic CAR‑T Race: CT0596 positions CARsgen (HKG: 2171) in the intensifying global competition to deliver off‑the‑shelf BCMA therapies that overcome the cost, manufacturing delay and accessibility limits of autologous CAR‑T.
- Plasma Cell Malignancy Breadth: Positive early signals in both R/R MM and primary plasma cell leukemia, plus planned expansion into other plasma cell malignancies, support a multi‑indication franchise strategy.
- Autoimmune Optionality: Planned exploration in autoreactive plasma cell–mediated autoimmune diseases aligns CT0596 with the rapidly emerging field of CAR‑T autoimmunity reset therapies, adding long‑term pipeline optionality.
- International Visibility: The EHA 2026 poster presentation provides European hematology‑community exposure for CT0596’s clinical dataset, supporting future global development discussions.
Forward‑Looking Statements
Under the cautionary statement required by Rule 18A.05 of the HKEX Listing Rules, the Company cannot guarantee that it will be able to develop, or ultimately market, CT0596 successfully. All non‑historical statements herein are forward‑looking, subject to significant risks and uncertainties detailed in the Company’s most recent annual and interim reports and other filings at www.carsgen.com; actual events or results may differ materially. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company, and no reliance should be placed on any projections, targets, estimates or forecasts contained in the announcement.-Fineline Info & Tech
